Ostenil/Ostenil Mini/Ostenil Plus

Sodium hyaluronate.

Ostenil & Ostenil Mini: 1 ml isotonic solution (pH 7) contains 10.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate and water for injections.
Ostenil Plus: 1 ml isotonic solution (pH 7) contains 20.0 mg sodium hyaluronate, sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
Ostenil: Sodium hyaluronate 1.0%. Viscoelastic solution for injection into the joint cavity for improvement of mobility and pain relief in osteoarthritis.
Ostenil Mini: Sodium hyaluronate 1.0%. Viscoelastic solution for injection into small joints for improvement of mobility and pain relief in osteoarthritis.
Ostenil Plus: Sodium hyaluronate 2.0%. Viscoelastic solution for injection into the joint cavity for improvement of mobility and pain relief in osteoarthritis.
Transparent solution of natural, highly purified sodium hyaluronate obtained by fermentation. Devoid of animal proteins. Sterile by moist heat. The content and the outer surface of the OSTENIL/OSTENIL MINI/OSTENIL PLUS pre-filled syringe are sterile if the sterile barrier is intact. For single use only.

Pharmacology: Characteristics and mode of action: Synovial fluid, which is viscoelastic due to the presence of hyaluronic acid, is found in all synovial joints, where it ensures normal, painless movement due to its lubricating and shock-absorbing properties. In degenerative joint disorders such as osteoarthritis, the viscoelasticity of the synovial fluid is markedly reduced thereby decreasing its lubricating and shock-absorbing functions. This increases mechanical loading of the joint and cartilage destruction which ultimately results in pain and restricted mobility of the affected joint. Supplementing this synovial fluid with intra-articular injections of highly purified hyaluronic acid can ameliorate the viscoelastic properties of synovial fluid. This improves its lubricating and shock-absorbing functions and reduces mechanical overload of the joint. Clinical trials showed a pain decrease and improvement in joint mobility up to six months.
Ostenil Plus: OSTENIL PLUS also contains mannitol, a free radical scavenger, which helps to stabilise the chains of sodium hyaluronate.

Ostenil & Ostenil Plus: Pain and restricted mobility of the knee and other big synovial joints like hip and shoulder.
Ostenil Mini: Pain and restricted mobility in degenerative and traumatic changes of small synovial joints, for example, the facet joints of the lumbar spine, the saddle joint of the thumb, the proximal joint of the big toe and the temporomandibular joint.

The sodium hyaluronate itself is degraded within a few days. Repeat treatment cycles may be administered as required. Take the pre-filled syringe out of the sterile pack, unscrew the Luer lock cap from the syringe, attach a suitable needle with Luer connector (for example 18 to 25 G) and secure it by turning slightly. Remove any air bubble, if present, before injection.
Ostenil: Inject OSTENIL into the affected joint once a week for a total of 3-5 injections. Several joints may be treated at the same time. Depending on the severity of the joint disease the beneficial effects of a treatment cycle of five intra-articular injections may last for six months or longer.
Ostenil Mini: Inject OSTENIL MINI into the affected joint once a week for a total of 1-3 injections. Several joints may be treated at the same time. Depending on the severity of the joint disease the beneficial effects of a treatment cycle of three intra-articular injections may last for six months or longer.
Ostenil Plus: Inject OSTENIL PLUS into the affected joint once a week for a total of 1-3 injections. Several joints may be treated at the same time. Depending on the severity of the joint disease the beneficial effects may last for six months or longer.

OSTENIL/OSTENIL MINI/OSTENIL PLUS should not be used in patients with ascertained hypersensitivity to any of its constituents.

The treatment with OSTENIL/OSTENIL MINI/OSTENIL PLUS is not recommended in children, pregnant and lactating women or in inflammatory joint diseases such as rheumatoid arthritis or Bechterew disease. In case of joint effusion, the effusion should be reduced first. The national guidelines for intra-articular injections must be observed, this includes thorough disinfection of the injection site and other measures to avoid joint infections. OSTENIL/OSTENIL MINI/OSTENIL PLUS should be injected accurately into the joint cavity, if necessary, under imaging control. Avoid injections into blood vessels or surrounding tissues. Do not use if the pre-filled syringe or sterile pack are damaged. Any solution not used immediately after opening must be discarded. Otherwise, the sterility is no longer guaranteed, and this may be associated with a risk of infection. Do not resterilize as this may damage the product. No information on the impairment of any diagnostic investigations, such as magnetic resonance imaging, clinical condition assessments or therapeutic treatments by OSTENIL/OSTENIL MINI/OSTENIL PLUS have been notified yet.

Ostenil & Ostenil Plus: In very rare cases (less than 1 in 10,000 patients) local secondary phenomena such as pain, feeling of heat, redness, swelling/joint effusion, pruritus and other local incompatibility reactions may occur during or after the injection of OSTENIL/OSTENIL PLUS. As with all invasive joint treatments, in very rare cases an infection may occur. It cannot be completely excluded that in very rare cases the intra-articular injection per se causes systemic side effects like tachycardia, hypotension, hypertension, palpitations, nausea and shortness of breath. Those reactions may occur independently from the solution applied. Before injecting OSTENIL/OSTENIL PLUS, the patient should be informed about contraindications and undesirable effects.
Ostenil Mini: In very rare cases (less than 1 in 10,000 patients) local secondary phenomena such as pain, feeling of heat, redness, swelling/joint effusion and tachycardia may occur during or after the injection of OSTENIL MINI. As with all invasive joint treatments, in very rare cases an infection may occur. Before injecting OSTENIL MINI, the patient should be informed about contraindications and undesirable effects.
Reporting of side effects: Any serious incident that has occurred in relation to the device should be reported to the manufacturer TRB Chemedica AG and the local competent authority of the user.

No information on the incompatibility of OSTENIL/OSTENIL MINI/OSTENIL PLUS with other medical devices and drugs for intra-articular use or oral analgesic or anti-inflammatory drugs have been notified yet.

Disposal: Put the used syringe in a sharps disposal container right away after use. Do not throw away the OSTENIL/OSTENIL MINI/OSTENIL PLUS prefilled syringe in the household trash. Follow the community guidelines for the right way to dispose of the sharps disposal container.

Store between 2°C and 25°C in a dry place, protected from light.

Other Drugs Acting on Musculo-Skeletal System

M09AX01 - hyaluronic acid ; Belongs to the class of other drugs for disorders of the musculo-skeletal system.